Press Releases
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/16/15Collegium Announces Publication of Nasal Human Abuse Potential Study in American Academy of Pain Medicine
CANTON, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the intranasal human abuse potential of Xtampza™ ER (oxycodone) extended-release capsules. The publication is titled “A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone.” In the published study, intranasal administrati... 
Printer Friendly Version
11/30/15Collegium to Present at the 27th Annual Piper Jaffray Healthcare Conference
CANTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that Michael Heffernan, the Company's Chairman and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference in New York City. The presentation will take place at 4:00 p.m. ET on Tuesday, December 1, 2015 at the New York Palace Hotel. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products ... 
Printer Friendly Version
11/12/15Collegium Reports Third Quarter Financial Results and Provides Corporate Update
CANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update. "During the last few months, Collegium achieved a number of important milestones in moving Xtampza™ ER closer to market launch upon final approval," stated Michael Heffernan, Collegium's CEO. "We were very encouraged by the FDA Advisory Committees' unanimous vote in support of approval of Xtampza ER a... 
Printer Friendly Version
11/09/15Collegium to Host Conference Call to Discuss Q3 Financial Results and Provide Corporate Update
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 12, 2015 at 8:00 a.m. ET. The Company will discuss its financial results for the third quarter of 2015 and provide a corporate update.  Topics in the corporate update will include: the recently announced FDA Tentative Approval for Xtampza™ ER and patent litigation with Purdue Pharma L.P.  Confere... 
Printer Friendly Version
11/09/15Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. With a tentative approval, the FDA h... 
Printer Friendly Version
10/12/15Collegium Provides Update on FDA Review of Xtampza(TM) ER, an Abuse-Deterrent Analgesic for the Treatment of Chronic Pain
CANTON, Mass., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has advised Collegium that it will not be able to complete its review of the New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules by the Prescription Drug User Fee Act (PDUFA) action date of October 12, 2015. "We are confident in the Xtampza ER program and our NDA submission. We continue to work closely with... 
Printer Friendly Version
09/11/15Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Sept. 11, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted unanimously to support the approval of Xtampza ER™ (oxycodone extended-release capsules) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alterna... 
Printer Friendly Version
09/04/15Collegium to Present Highlights From Xtampza(TM) ER (Oxycodone Extended-Release Capsules) Clinical Development Program at PAINWeek
CANTON, Mass., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that it will present data from the clinical development program for Xtampza™ ER, an abuse-deterrent, extended-release oral formulation of oxycodone, at PAINWeek 2015, taking place September 8-12, 2015 at The Cosmopolitan in Las Vegas. The five posters include results from a series of studies that evaluate the abuse-deterrent properties of Xtampza ER, conducted in accordance with guid... 
Printer Friendly Version
08/24/15Collegium Publishes Data From Xtampza(TM) ER Phase 3 Clinical Trial in the Journal PAIN
CANTON, Mass., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the Phase 3 clinical trial of Xtampza™ ER (oxycodone extended-release capsules). The study is titled "A phase 3, multi-center, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain" and was published online in the August issue of the peer-reviewed journ... 
Printer Friendly Version
08/12/15Collegium Reports Second Quarter Financial Results and Provides Corporate Update
CANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update. Michael Heffernan, Collegium's Chairman and CEO, stated, "During the second quarter, Collegium achieved a number of important milestones. The successful completion of our IPO in May 2015 provides us with substantial additional resources to launch Xtampza™ ER pending final approval by the FDA and to m... 
Printer Friendly Version
08/07/15Collegium to Host Conference Call to Discuss Financial Results and Provide Corporate Update
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13, 2015 at 8:00 a.m. ET. The Company will discuss its financial results for the second quarter of 2015 and provide a corporate update. Topics in the corporate update will include: commercial organization progress, the recently announced FDA Advisory Committee meeting for Xtampza™ ER and patent litigat... 
Printer Friendly Version
08/07/15Collegium Announces FDA Advisory Committee Meeting for Xtampza(TM) ER, an Abuse-Deterrent Analgesic for Chronic Pain
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone extended-release capsules) on September 11, 2015. Xtampza ER, Collegium's lead product candidate, is an abus... 
Printer Friendly Version
07/06/15Collegium Added to Russell 2000(R), 3000(R) and Global Indexes
CANTON, Mass., July 6, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place on June 26, 2015. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10% of the total market capitalization of that index.... 
Printer Friendly Version
07/01/15Collegium Expands Leadership Team With Vice President of Regulatory Affairs and Quality Assurance
CANTON, Mass., July 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that John (Jack) Weet, Ph.D., has joined the company as its Vice President of Regulatory Affairs and Quality Assurance. Dr. Weet will oversee Collegium's Regulatory Affairs and Quality Assurance, providing oversight for all U.S. and international filings and interactions with regulatory authorities. Prior to joining Collegium, Dr. Weet was Vice President of Regulatory Affairs at Durat... 
Printer Friendly Version
06/25/15Collegium Announces Publication of "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations With Abuse-Deterrent Properties," in Pain Medicine
CANTON, Mass., June 25, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of a comparative clinical trial titled "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties," in the peer-reviewed medical journal, Pain Medicine. The objective of the clinical trial was to assess the safety and pharmacokinetics of Xtampza ER when the capsule was taken in... 
Printer Friendly Version
06/15/15Collegium to Present Xtampza ER(TM) Oral Human Abuse Potential Data at the College on Problems of Drug Dependence 77th Annual Meeting
CANTON, Mass., June 15, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the presentation of a scientific poster at the College on Problems of Drug Dependence 77th Annual Meeting, held at the Arizona Biltmore in Phoenix, AZ from June 13 to June 18. The poster, titled "Oral Human Abuse Potential of Oxycodone DETERx®: An Abuse-deterrent, Extended-release Formulation in Recreational Opioid Users", summarizes data from a human abuse potential (HAP) study desi... 
Printer Friendly Version
06/08/15Collegium Announces Issuance of U.S. Patent Covering DETERx(R) - an Abuse-Deterrent, Extended-Release Technology Platform
Additional Patent Coverage for Lead Product, Xtampza ER(TM) CANTON, Mass., June 8, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,044,398 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Abuse-deterrent Pharmaceutical Compositions of Opioids and Other Drugs". The issued patent covers the DETERx technology platform and Collegium's lead product candidate, Xtampza ER (oxycodone extended-re... 
Printer Friendly Version
06/01/15Collegium Expands Commercial Organization With Key Appointments
CANTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the addition of Barry Duke as Executive Vice President and Chief Commercial Officer. In addition to Mr. Duke, Mary Ogle joined as Vice President of Marketing and Timothy Hermes as Vice President of Government Affairs and Alliance Development. "Barry's deep experience, in both small and large organizations make him a great fit to lead our commercial organization as we prepare for FDA a... 
Printer Friendly Version
05/27/15Collegium to Present at the Jefferies 2015 Global Healthcare Conference
CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday, June 1, 2015 at 1:30pm Eastern Time. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETE... 
Printer Friendly Version
05/12/15Collegium Pharmaceutical Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
CANTON, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions, including shares issued upon the exercise of the underwriters' option to purchase additional shares, resulting in gross proceeds of $80.0 million. The company's shares began trading on The NASDAQ Global Select Marke... 
Printer Friendly Version
05/07/15Collegium Pharmaceutical Announces Pricing of Its Initial Public Offering
CANTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., (Nasdaq:COLL) today announced the pricing of its initial public offering of 5,800,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Collegium. In addition, Collegium has granted the underwriters a 30-day option to purchase from Collegium up to an additional 870,000 shares of common stock. Colle... 
Printer Friendly Version
03/17/15Collegium Pharmaceutical to Present Xtampza ER™ Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting
Canton, MA – March 17, 2015 – Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company’s completed Phase III clinical trial that evaluated the efficacy and safety of its lead drug candidate, Xtampza ER™, an abuse-deterrent, extended-release analgesic for chronic pain. The poster will be presented at the American Academy of Pain Medicine’s (AAPM) 31st Annual Meeting, being heldon March 19-22, 2015 at the Gaylord National Resort and Convention Center, National Harbor, Ma... 
Printer Friendly Version
03/10/15Collegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of its Lead Abuse-Deterrent Product Candidate
Funding follows NDA acceptance of Xtampza ER™ in February 2015Canton, MA – March 10, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that it has raised a $50 million financing. Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER (oxycodone extended-release capsul... 
Printer Friendly Version
02/26/15Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Xtampza ER™ utilizes the DETERx Technology PlatformCanton, MA – February 26, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that Application No. 13/551,455, an application relating its DETERx technology platform, was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The patent contains claims that p... 
Printer Friendly Version
02/12/15Collegium Pharmaceutical Announces FDA Acceptance for Filing of NDA for Xtampza ER™ (oxycodone extended-release capsules), an Abuse-Deterrent Analgesic for Chronic Pain
Canton, MA – February 12, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for Xtampza ER, its novel, abuse-deterrent, extended-release oxycodone formulation for the treatment of chronic pain. Xtampza ER is Collegium... 
Printer Friendly Version
02/09/15Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to Its Board of Directors
Management team significantly strengthened by adding financial expertiseCanton, MA – February 9, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced today the appointments of Paul Brannelly as Executive Vice President and Chief Financial Officer and Garen Bohlin to its Board of Directors, effective immediately.“Adding Paul to Collegium’s m... 
Printer Friendly Version
01/15/15“Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain with Dysphagia (CPD),” Published in Pain Practice
Clinical study demonstrates that the Xtampza ER™ ER (oxycodone extended-release) drug release profile is maintained when sprinkled onto foodCanton, MA – January 15, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of “Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD),... 
Printer Friendly Version